参考文献/References:
[1] Li YZ,Teng D,Ba JM,et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders:epidemiological evidence from 31 provinces of mainland China[J].Thyroid,2020,30(4):568-579.DOI:10.1089/thy.2019.0067.
[2] Shan ZY,Chen LL,Lian XL,et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China:a cross-sectional study in 10 cities[J].Thyroid,2016,26(8):1125-1130.DOI:10.1089/thy.2015.0613.
[3] Teng WP,Shan ZY,Teng XC,et al. Effect of iodine intake on thyroid diseases in China[J].N Engl J Med,2006,354(26):2783-93.DOI:10.1056/NEJMoa054022.
[4] Teng D,Yang WQ,Shi XG,et al. An inverse relationship between iodine intake and thyroid antibodies: a national cross-sectional survey in mainland China[J].Thyroid,2020,30(11):1656-1665.DOI:10.1089/thy.2020.0037.
[5] Ross DS,Burch HB,Cooper DS,et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[6] 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会,中华医学会内分泌学分会,中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南(第2版)[J].中华内分泌代谢杂志,2019,22(8):636-665.DOI:10.3760/cma.j.issn.1000-6699.2019.08.003.
[7] Haugen BR,Alexander EK,Bible KC,et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[8] Fan YF,Xu SH,Zhang HF,et al. Selenium supplementation for autoimmune thyroiditis:a systematic review and meta-analysis[J].Int J Endocrinol,2014,2014:904573.DOI:10.1155/2014/904573.
[9] Wichman J,Winther KH,Bonnema SJ,et al. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis:a systematic review and meta-analysis[J].Thyroid,2016,26(12):1681-1692.DOI:10.1089/thy.2016.0256.
[10] Wang WW,Mao JY,Zhao JJ,et al. Decreased thyroid peroxidase antibody titer in response to selenium supplementation in autoimmune thyroiditis and the influence of a selenoprotein P gene polymorphism:a prospective,multicenter study in China[J].Thyroid,2018,28(12):1674-1681.DOI:10.1089/thy.2017.0230.
[11] Wang S,Wu YP,Zuo ZH,et al. The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis:a systematic review and a meta-analysis[J].Endocrine,2018,59(3):499-505.DOI:10.1007/s12020-018-1532-5.
[12] Liu ZW,Masterson L,Fish B,et al. Thyroid surgery for Graves' disease and Graves' ophthalmopathy[J].Cochrane Database Syst Rev,2015,25(11):CD010576.DOI:10.1002/14651858.CD010576.pub2.
[13] Bartalena L,Baldeschi L,Boboridis K,et al. The 2016 European Thyroid Association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[14] Pearce SHS,Dayan C,Wraith DC,et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism:a phase Ⅰ study[J].Thyroid,2019,29(7):1003-1011.DOI:10.1089/thy.2019.0036.
[15] Wu LP,Xun LR,Yang J,et al. Induction of murine neonatal tolerance against Graves' disease using recombinant adenovirus expressing the TSH receptor A-subunit[J].Endocrinology,2011,152(3):1165-1171.DOI:10.1210/en.2010-0737.
[16] Chin YH,Ng CH,Lee MH,et al. Prevalence of thyroid eye disease in Graves' disease:a meta-analysis and systematic review[J].Clin Endocrinol(Oxf),2020,93(4):363-374.DOI:10.1111/cen.14296.
[17] Wang CJ,Ning QY,Jin K,et al. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? a systematic review and meta-analysis[J].BMC Ophthalmol,2018,18(1):46.DOI:10.1186/s12886-018-0679-4.
[18] Wiersinga WM. Advances in treatment of active,moderate-to-severe Graves' ophthalmopathy[J].Lancet Diabetes Endocrinol,2017,5(2):134-142.DOI:10.1016/S2213-8587(16)30046-8.
[19] Douglas RS,Kahaly GJ,Patel A,et al. Teprotumumab for the treatment of active thyroid eye disease[J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[20] Smith TJ,Kahaly GJ,Ezra DG,et al. Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[21] Osorio JC,Ni A,Chaft JE,et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J].Ann Oncol,2017,28(3):583-589.DOI:10.1093/annonc/mdw640.
[22] Haanen JBAG,Carbonnel F,Robert C,et al. Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2017,28(Suppl_4):iv119-iv142.DOI:10.1093/annonc/mdx225.